DOCSLIB.ORG

DDT Cover/Back April 2006.Qx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DDT Cover/Back April 2006.Qx March 2008 Vol 8 No 3 www.drugdeliverytech.com IN THIS ISSUE INTERVIEW WITH SCOLR PHARMA’S PRESIDENT & CEO MR. DANIEL O. WILDS Excipient Quality & Sourcing 30 Chris Moreton, PhD Bill Webb Non-Invasive Insulin 43 Avani Amin, PhD Tejal Shah, MPharm Life-Cycle Management 52 Douglas Martin, MD Calculating Solubility 56 Hannah Batchelor, PhD Rachael Myatt FEATURING The science & business of specialty pharma, biotechnology, and drug delivery Improving Ms. Cindy H. Taneli Mr. Daniel Vaccines 74 Dubin Jouhikainen, Ruppar Ronald Ellis, PhD Analytical MD, PhD, MBA Hurdles in Oral Laboratories: Addressing the Product Trends, Analgesic Gap in Development & Medical the Need for Management & Breakthrough 77 Relationships Cancer Pain Continued Diversity Investment Udo Kiessling, MD, PhD March 2008 Vol 8 No 3 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie Malcolm A. Teasdale TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Fax: (703) 548-3733 E-mail: [email protected] E-mail: [email protected] West Coast Warren De Graff Western Regional Manager The bi-weekly electronic newsletter from the publishers of Drug 818 5th Avenue, Suite 301 San Rafael, CA 94901 Delivery Technology and Specialty Pharma will provide over 12,000 Tel: (415) 721-0644 Fax: (415) 721-0665 subscribers with the latest news of business deals, alliances, and E-mail: [email protected] technology breakthroughs from the pharmaceutical, specialty International Ralph Vitaro pharmaceutical, drug delivery, and biotechnology industries. 219 Changebridge Road Montville, NJ 07045 3 Tel: (973) 299-1200 o There are a limited amount of sponsorship opportunities available. N Fax: (973) 299-7937 8 Please contact us for more information: E-mail: [email protected] l o V Mailing List Rental 8 East & Midwest – Victoria Geis • Tel: (703) 212- 7735 Candy Brecht 0 0 Tel: (703) 706-0383 2 [email protected] h Fax: (703) 549-6057 c r a E-mail: [email protected] M West – Warren DeGraff • Tel: (415) 721-0664 All editorial submissions are handled with reasonable care, but the publishers assume no responsibility for the safety y g of artwork, photographs, or manuscripts. Every precaution is taken to ensure accuracy, but publishers cannot accept o l [email protected] responsibility for the accuracy of information supplied herein or for any opinion expressed. Drug Delivery Technology o n (ISSN 1537-2898) is published 10 times in 2008, January, February, March, April, May, June, July/August, September, h c October, and November/December by Drug Delivery Technology LLC, 219 Changebridge Road, Montville NJ 07045. e T Subscription rates: $99.00 for 1 year in the United States, Canada, and Mexico. $153.00 for 1 year outside the United y States, Canada, and Mexico. All subscriptions are payable in US funds, drawn on US banks. Send payment to: Drug r International - Ralph Vitaro • Tel: (973) 263-5476 e Delivery Technology LLC subscription Department, 219 Changebridge Road, Montville NJ 07045. Single copies (prepaid) v i l $15.00, US, Canada, and Mexico; $24.00 in all other countries. Add $5.00 per order for shipping and handling. e [email protected] D Periodicals Postage Paid at Montville, NJ 07045-9998 and additional mailing offices. Postmaster: please send address g changes to Drug Delivery Technology, 219 Changebridge Road, Montville NJ 07045. All rights reserved under the US u r International and Pan-American Copyright Conventions. All rights reserved. No part of this publication may be D reproduced or transmitted in any form or by any means, electronic or mechanical, including by photocopy, recording, or information storage and retrieval system, without written permission from the publisher. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Drug Delivery 4 Technology LLC for libraries and other users registered with the Copywrite Clearance, 222 Rosewood Drive, Danvers, MA 01923; phone: (978) 750-8400, fax: (978) 750-4470. 34 The Management Buy-Out: What’s a Fair Price? Derrek G. Hennecke, MBA, continues with part 2 of his 7- part series chronicling the challenges, issues, and more importantly, the opportunities he faced throughout his Management Buy-Out. 38 Addressing the Analgesic Gap in Breakthrough Cancer Pain – A Drug Delivery Case Study Josef Bossart, PhD, and Taneli Jouhikainen, MD, PhD, review some of the thinking and strategies being implemented to fill or bridge the Analgesic Gap through the rational application of drug delivery technology. 43 Annual Update on Non-Invasive Insulin Delivery Technologies Avani Amin, MPharm, PhD; Tejal Shah, MPharm; Jagruti Patel, MPharm, PhD; and Anuradha Gajjar, MPharm, PhD; present an update on the progress of the non-invasive delivery technologies for insulin since last year’s update featured in the March 2007 issue of this publication. 50 Oral Drug Delivery: Hurdles in Oral Product Development & the Need for Continued Technology Investment Daniel Ruppar believes as biopharmaceutical and specialty pharma products expand the importance of revenue streams for companies in the future, continued investment in oral technologies to deliver these products to patients is expected to become increasingly important. 52 Life Cycle Management: Taking an “The obvious solution to bridging the Aggressive Approach Analgesic Gap is to deliver fentanyl Douglas Martin, MD, suggests taking an aggressive “strategic innovation” approach to leverage years of 3 o N over a much larger surface area. This research to identify molecular entities similar to an expiring 8 l blockbuster and erecting new exclusivity barriers for these o V concept is being developed with two follow-on drugs by targeting strategically chosen 8 0 0 indications. 2 newer approaches (delivery to the nasal h c r a M mucosa and to the lungs), both of 56 Measuring the Solubility of a Model Drug in y g o Drug-in-Adhesive Transdermal Patches to l o which have a large surface area and n h Validate a Theoretical Solubility Calculator c e T Rachael Myatt, Gbolahan Oladiran, and Hannah Batchelor, y like the oral mucosa, are rich in drug r e v PhD, provide research to validate the use of a theoretical i l e D permeable vasculature.” solubility calculator by comparing the solubility of sodium g u r D fluorescein, a model hydrophilic drug, in a range of DURO- p.38 TAK adhesives using Higuchi kinetics to measure the 6 experimental solubility. 60 SCOLR Pharma, Inc.: A Differentiated Oral Drug Delivery Company Drug Delivery Executive: Daniel O. Wilds, President and CEO of SCOLR, discusses how his company intends to “Pertinent questions the client should ask commercialize products independently and through third- the laboratory are: 1) Does the laboratory party alliances with pharmaceutical and other industry partners utilizing its unique CDT delivery platform. have detailed and current SOPs and an 66 Analytical Laboratories: Trends, effective quality group; 2) Has the Management & Relationships laboratory been successfully audited by Contributor Cindy H. Dubin recently asked several of the industry’s leading analytical laboratories about trends in the the FDA recently; 3) Does the laboratory sector, project management, and how Specialty Pharma have the instrumentation and the level of companies can best manage relationships with providers. expertise needed for the project; and 4) Is 74 NasVax: Improving Vaccines With a Unique Platform it possible to discuss data directly with Executive Summary: Dr. Ronald Ellis, Senior VP & CTO for the analysts working on your project?” NasVax, discusses how the company built up its management team, completed two private investment rounds, and had a successful IPO to become a publicly traded company on the Tel Aviv Stock Exchange. 77 The Challenges of Medical Diversity Udo Kiessling, MD, PhD, questions whether different therapeutic areas and various diseases require a specific approach in drug development, highlighting key differences among three major therapeutic areas with regard to success rates in clinical development. DEPARTMENTS Market News & Trends . .. 12 Business Development . .. 22 What is the Value of Your Company? 3 3 Combination Update . .. 26 o o N N 7 Understanding the Regulatory Environment 8 l l o o V for Combination Products in the World’s V 7 8 0 Leading Markets 0 0 0 2 2 h h c r Excipient Update . .. 30 c r a a M M Big Pharma & Suppliers Collaborate y y g g o o on Excipient Quality l l o o n n h h c c e e Technology Showcase . .. 64 T T y y r r e e v v i i Facts & Figures . 73 l l e e D D g g u u External Delivery . .. 82 r r D D SARs Analysis 8 p.66 9 Drug Delivery Technology April 2006 Vol 6 No 4 Dan Marino, MSc Executive Editorial Director Drug Delivery Technology Shaukat Ali, PhD, MSc John A. Bermingham Der-Yang Lee, PhD Technical Service Manager President & CEO Research Fellow, R&D BASF Pharma Solutions The Lang Companies Technology, R&D Labs McNeil Consumer Healthcare, Johnson & Johnson Sarath Chandar, MBA Derek G. Hennecke, MBA Gary W. Cleary, PhD, Vice President, Global President & CEO PharmD, MBA Marketing & Commercial Xcelience President & CTO Development Corium International SPI Pharma Ms. Debra Bingham James N. Czaban, JD John Fraher Partner Partner, FDA Department President, North America Valeo Partners WilmerHale Eurand Philip Green, PhD Keith Horspool, PhD Ali Rajabi-Siahboomi, Director of Business Director, Research PhD Development Formulations Global Technical Director, Modified Release Advanced Drug Delivery Pfizer Global Research & Technologies Development BD Colorcon David Monteith, PhD, MBA Uday B.
Load more

Recommended publications
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • Interleukin-2 Fusion Toxins Ders
    2326 Supplementary Drugs and Other Substances Interleukin-1 Receptor Antagonists 3. Nishimoto N. Clinical studies in patients with Castleman’s dis- that children with a rare inherited susceptibility to fatal mycobac- ease, Crohn’s disease, and rheumatoid arthritis in Japan. Clin Antagonista del Receptor de la Interleucina 1; IL-1ra; IL-1i; Inter- terial infections exhibit mutations in the interleukin-12 gene. In- Rev Allergy Immunol 2005; 28: 221–30. terleukin-12 is also under study for the treatment of various can- leukin-1 Inhibitors. 4. Yokota S, et al. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy cers, including as adenovirus-mediated gene therapy. Profile Immunol 2005; 28: 231–8. Edodekin alfa is human recombinant interleukin-12 under inves- Endogenous antagonists to interleukin-1 receptor block the ac- 5. Lipsky PE. Interleukin-6 and rheumatic diseases. Arthritis Res tigation for the treatment of renal cell carcinoma. tions of interleukin-1 (p.2325) and recombinant forms have been Ther 2006; 8 (suppl 2): S4. Available at: http:// arthritis-research.com/content/8/S2/S4 (accessed 11/02/08) ◊ References. investigated in inflammatory and immune-modulated disorders. 6. Maini RN, et al. Double-blind randomized controlled clinical 1. Mazzolini G, et al. Gene therapy of cancer with interleukin-12. Anakinra (p.19) is a human recombinant interleukin-1 receptor trial of the interleukin-6 receptor antagonist, tocilizumab, in Eu- Curr Pharm Des 2003; 9: 1981–91. antagonist used in the treatment of rheumatoid arthritis. ropean patients with rheumatoid arthritis who had an incom- plete response to methotrexate.
    [Show full text]
  • P,Reparati?.Ns Preparations
    ,reparati ns Bonjigar (EoH)l)KHrap); Entoban (3Hro6aH); Pilex (ITaiilleKc); solutions have a blue or bluish-purple colour. Store in P ?. Ukr.: Bonjigar (EoH,ll)KHrap); Entoban (3HT06aH). airtight containers at a temperature of 2 5 degrees, Proprietary Preparations (details are given in Volume B) excursions permitted between 15 degrees and 30 degrees. Single-ingredient Preparations. Austria: Elaprase; Belg.: Ela­ Protect from light. prase; Canad.: Elaprase; Cz.: Elaprase; Denm.: Elaprase; Fr.: Indian Gooseberry Elaprase; Ger.: Elaprase; Gr.: Elaprase; Hong Kong: Elaprase; Uses and Administration Hung.: Elaprase; Irl. : Elaprase; Israel: Elaprase; Jpn: Elaprase; Malaysia: Elaprase; Neth.: Elaprase; Norw.: Elaprase; NZ: Ela­ On intravenous injection indigo carmine is rapidly excreted, prase; Pol.: Elaprase; Port.: Elaprase; Spain: Elaprase; Swed. : mainly by the kidneys. It has been used in a test of renal Elaprase; Switz.: Elaprase; UK: Elaprase; USA: Elaprase. function, but has largely been replaced by agents that give more precise results. It is used as a marker dye, particularly in urological procedures, when it is given in a usual dose of 40 mg, preferably by intravenous injection but sometimes Ignatia NOTE. The common name myrobalan or myrobalans refers to several unrelated fruit-bearing plant species from the intramuscularly. It has also been used as a marker dye in Eeve de Bean; Song genera Emblica (Emblica officinalis, Emblic Myrobalan or amniocentesis. St :iaint-l'i)nace; ignatia ar:rara; Ignatius Lv Guq; ignqtius' �an. Indian Gooseberry, above), Prunus (P. cerasife ra, Myrobalan Indigo carmine has been used as a blue dye in medicinal preparations but it is relatively unstable. It has also been A TC Herb· ,-- HA09WAS023 Plum), and Terminalia (T.
    [Show full text]
  • Effects of IL-6 Signaling Pathway Inhibition on Weight And
    International Journal of Molecular Sciences Review Effects of IL-6 Signaling Pathway Inhibition on Weight and BMI: A Systematic Review and Meta-Analysis Olivia Patsalos 1 , Bethan Dalton 1 and Hubertus Himmerich 1,2,* 1 Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London SE5 8AF, UK; [email protected] (O.P.); [email protected] (B.D.) 2 South London and Maudsley NHS Foundation Trust, London SE5 8AZ, UK * Correspondence: [email protected]; Fax: +44-20-78-48-01-82 Received: 7 August 2020; Accepted: 25 August 2020; Published: 31 August 2020 Abstract: Inhibitors of the IL-6 signaling pathway, such as tocilizumab, are frequently administered for the treatment of immune diseases, e.g., rheumatoid arthritis and multicentric Castleman’s disease. The aim of this systematic review and meta-analysis was to ascertain the effects of IL-6 pathway inhibitors on weight and body mass index (BMI). Using PRISMA guidelines, we systematically reviewed relevant articles from three databases (PubMed, OVID, EMBASE). A random effects model was used to estimate standardized mean change (SMCC). Ten studies with a total of 1531 patients were included in the meta-analysis for weight and ten studies with a total of 1537 patients were included in the BMI meta-analysis. The most commonly administered IL-6 pathway inhibitor was tocilizumab. IL-6 pathway inhibitors were associated with increases in weight (SMCC = 0.09, p = 0.016, 95% CI [0.03, 0.14]) and BMI (SMCC = 0.10, p = 0.0001, 95% CI [0.05, 0.15]).
    [Show full text]
  • Multiple Myeloma Multiple Myeloma Bone Marrow Research Multiple Myeloma Copyright © 2011 Hindawi Publishing Corporation
    Bone Marrow Research Multiple Myeloma Multiple Myeloma Bone Marrow Research Multiple Myeloma Copyright © 2011 Hindawi Publishing Corporation. All rights reserved. This is a focus issue published in volume 2011 of “Bone Marrow Research.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board Joseph H. Antin, USA Hans Jochem Kolb, Germany PeterJ.Quesenberry,USA Igor W. Blau, Germany Robert B. Levy, USA Shahin Rafii, USA Catherine Bollard, USA Mark R. Litzow, USA Voravit Ratanatharathorn, USA Paolo De Fabritiis, Italy Fausto Loberiza, USA David A. Rizzieri, USA Yigal Dror, Canada David Ma, Australia Patrick J. Stiff,USA Csar O. Freytes, USA Ignazio Majolino, Italy Anna Sureda, Spain A. Ganser, Germany Philip L. McCarthy, USA Guido J. K. Tricot, USA Eva C. Guinan, USA Kenneth R. Meehan, USA Celalettin Ustun, USA Kais Hussein, Germany Paul V. O’Donnell, USA Catherine Verfaillie, Belgium Issa F. Khouri, USA Helen A. Papadaki, Greece Axel R. Zander, Germany Hans Klingemann, USA Finn B. Petersen, USA Guido Kobbe, Germany Luis F. Porrata, USA Contents Antibody-Based Therapies in Multiple Myeloma, Yu-Tzu Tai and Kenneth C. Anderson Volume 2011, Article ID 924058, 14 pages A Case of Monoclonal Lymphoplasmacytosis of the Bone Marrow with IgM-Positive Russell Bodies, Hidekazu Kayano, Tsuneyuki Shimada, Naoki Wakimoto, Yuichi Nakamura, Masami Bessho, Hiroshi Yamaguchi, Atsushi
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
    Pure Appl. Chem., Vol. 84, No. 5, pp. 1113–1295, 2012. http://dx.doi.org/10.1351/PAC-REC-11-06-03 © 2012 IUPAC, Publication date (Web): 16 February 2012 IUPAC glossary of terms used in immunotoxicology (IUPAC Recommendations 2012)* Douglas M. Templeton1,‡, Michael Schwenk2, Reinhild Klein3, and John H. Duffus4 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; 2In den Kreuzäckern 16, Tübingen, Germany; 3Immunopathological Laboratory, Department of Internal Medicine II, Otfried-Müller-Strasse, Tübingen, Germany; 4The Edinburgh Centre for Toxicology, Edinburgh, Scotland, UK Abstract: The primary objective of this “Glossary of Terms Used in Immunotoxicology” is to give clear definitions for those who contribute to studies relevant to immunotoxicology but are not themselves immunologists. This applies especially to chemists who need to under- stand the literature of immunology without recourse to a multiplicity of other glossaries or dictionaries. The glossary includes terms related to basic and clinical immunology insofar as they are necessary for a self-contained document, and particularly terms related to diagnos- ing, measuring, and understanding effects of substances on the immune system. The glossary consists of about 1200 terms as primary alphabetical entries, and Annexes of common abbre- viations, examples of chemicals with known effects on the immune system, autoantibodies in autoimmune disease, and therapeutic agents used in autoimmune disease and cancer. The authors hope that among the groups who will find this glossary helpful, in addition to chemists, are toxicologists, pharmacologists, medical practitioners, risk assessors, and regu- latory authorities. In particular, it should facilitate the worldwide use of chemistry in relation to occupational and environmental risk assessment.
    [Show full text]
  • International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
    INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 15/06/2006 INTERNATIONAL NONPROPRIETARY NAMES (INN) FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES (A REVIEW) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines (QSM) Medicines Policy and Standards (PSM) Department CONTENTS 0. INTRODUCTION…………………………………….........................................................................................v 1. PHARMACOLOGICAL CLASSIFICATION OF BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES……………………………………................................1 2. CURRENT STATUS OF EXISTING STEMS OR SYSTEMS FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES…………………….3 2.1 Groups with respective stems ……………………………………………………………………3 2.2 Groups with respective pre-stems………………………………………………………………4 2.3 Groups with INN schemes………………………………………………………………………….4 2.4 Groups without respective stems / pre-stems and without INN schemes…..4 3. GENERAL POLICIES FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES……………………………………………………………………………………………………...5 3.1 General policies for blood products……………………………………………………………5 3.2 General policies for fusion proteins……………………………………………………………5 3.3 General policies for gene therapy products………………………………………………..5 3.4 General policies for glycosylated and non-glycosylated compounds………...6 3.5 General policies for immunoglobulins……………………………………………………….7 3.6 General polices for monoclonal antibodies………………………………………………..7 3.7 General polices for skin substitutes……………………………………………………………9 3.8 General policies for transgenic products……………………………………………………9
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 38/16 (2006.01) A61K 39/395 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 39/00 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (21) International Application Number: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PCT/US20 16/042074 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (22) International Filing Date: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 13 July 2016 (13.07.2016) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (30) Priority Data: TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/192,269 14 July 2015 (14.07.2015) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 62/197,966 28 July 2015 (28.07.2015) US DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 62/277,201 11 January 2016 ( 11.01.2016) u s LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (71) Applicant: IMMUNEXT, INC.
    [Show full text]